Janus Henderson Group PLC Increases Stock Position in Collegium Pharmaceutical, Inc. $COLL

Janus Henderson Group PLC lifted its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 26.0% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,825,651 shares of the specialty pharmaceutical company’s stock after buying an additional 377,073 shares during the period. Janus Henderson Group PLC owned approximately 5.63% of Collegium Pharmaceutical worth $60,358,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in COLL. Vanguard Group Inc. raised its holdings in shares of Collegium Pharmaceutical by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock worth $104,465,000 after purchasing an additional 29,876 shares during the period. Massachusetts Financial Services Co. MA grew its holdings in shares of Collegium Pharmaceutical by 65.3% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,312,655 shares of the specialty pharmaceutical company’s stock worth $60,776,000 after purchasing an additional 518,721 shares during the period. Louisiana State Employees Retirement System purchased a new stake in shares of Collegium Pharmaceutical during the 1st quarter worth about $463,000. Intech Investment Management LLC increased its position in Collegium Pharmaceutical by 25.5% during the 4th quarter. Intech Investment Management LLC now owns 108,855 shares of the specialty pharmaceutical company’s stock worth $5,040,000 after purchasing an additional 22,146 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Collegium Pharmaceutical during the 1st quarter worth approximately $686,000.

Analysts Set New Price Targets

A number of brokerages have weighed in on COLL. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Collegium Pharmaceutical in a research report on Monday, July 6th. Zacks Research lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Truist Financial raised shares of Collegium Pharmaceutical to a “strong-buy” rating in a research note on Monday, June 15th. Finally, Wall Street Zen lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 25th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Collegium Pharmaceutical Stock Performance

Shares of NASDAQ:COLL opened at $35.39 on Friday. The company has a market cap of $1.15 billion, a P/E ratio of 17.35 and a beta of 0.73. The company has a debt-to-equity ratio of 2.47, a quick ratio of 1.62 and a current ratio of 1.71. Collegium Pharmaceutical, Inc. has a one year low of $29.19 and a one year high of $50.79. The business’s 50-day simple moving average is $34.84 and its 200 day simple moving average is $37.55.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share for the quarter, beating analysts’ consensus estimates of $1.52 by $0.24. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The business had revenue of $193.52 million during the quarter, compared to analyst estimates of $184.47 million. During the same period last year, the business earned $1.49 EPS. The business’s revenue was up 8.9% on a year-over-year basis. On average, sell-side analysts forecast that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current fiscal year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.